

Can improved housing provide additional protection against clinical malaria over current best practice?

Submission date 05/09/2014	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 23/09/2014	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 13/04/2021	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Malaria is a life-threatening infection that people can get through bites by infected mosquitoes (malaria mosquitoes). It is one of the greatest threats to global public health; in 2012 there were 207 million cases of the condition resulting in 627,000 deaths with some 80% of those deaths occurring in Africa. Most cases of infection happen indoors at night, so it's important to try and prevent, or at least reduce, the number of malaria mosquitoes entering people's homes. In previous research, we have shown that closing the eaves (the gap between the top of the wall and the roof) and using screening can reduce dramatically the number of malaria mosquitoes entering a house. Here, we want to find out if we can protect children against malaria by modifying houses so that they have a metal roof, closed eaves, screened doors and windows and screened air bricks which allow the warm air to rise out of the house, but not let any mosquitoes indoors. We will see how successful these measures are by looking at how many children become infected in these houses compared to those living in houses with thatched roofs and open eaves. Over the past thirty years a silent revolution in house design has been happening across Africa. The traditional thatched-roofed houses are being replaced steadily by metal-roofed houses as the continent develops. We hope to ride this wave of cultural change and further improve the design of houses to make them healthier to live in. Improved housing has the potential to improve the lives of millions of people across sub-Saharan Africa.

Who can participate?

Children aged 6 months to 13 years who live in single-story homes with thatched roofs, walls without cracks, open eaves, have no more than 4 rooms, no ceiling and no screening.

What does the study involve?

Households in eligible housing are randomly allocated into one of two groups. Those in the intervention group have their homes modified to have metal roofs, closed eaves, screened-air bricks and screening on the doors and windows. Those in the control group do not have their homes modified.

What are the possible benefits and risks of participating?

The study participants will benefit from the intense follow up as any illness, including clinical malaria, will be diagnosed and treated. Most importantly, participants will benefit by having a better quality house at the beginning or end of the study, i.e. those in the control group will be offered the modifications at the end of the study. There is a low risk that well-sealed houses may increase the risk of respiratory disease in children. However, we will monitor this during the study. Children with respiratory disease will be referred to local health facilities for treatment.

Where is the study run from?

The study will take place in The Gambia, but run from Durham University (UK)

When is the study starting and how long is it expected to run for?

November 2014 to February 2017

Who is funding the study?

Global Health Trials (MRC-DfID-Wellcome Trust) (UK)

Who is the main contact?

Professor Steve Lindsay

s.w.lindsay@durham.ac.uk

Contact information

Type(s)

Scientific

Contact name

Prof Steve Lindsay

Contact details

School of Biological and Biomedical Sciences

Durham University

Science Laboratories

South Road

Durham

United Kingdom

DH1 3LE

+44 (0)191 334 1291

S.W.Lindsay@durham.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Version 0.1

Study information

Scientific Title

Can improved housing provide additional protection against clinical malaria over current best practice? A household-randomised controlled study

Acronym

RooPfs

Study objectives

Improved housing will reduce house entry by malaria mosquitoes and thereby reduce the incidence of clinical malaria in children living in these houses.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. The Gambia Government/MRC Joint Ethics Committee, 29/10/2014, SCC 1390v3
2. Durham University School of Biological and Biomedical Sciences Ethics Committee, 01/12/2014, Ref: SBBS/EC/1401/RooPfs 12 09 14

Study design

Two-armed household clustered-randomised controlled study

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Study setting(s)

Home

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Malaria

Interventions

All study houses will be provided with a sufficient number of LLINs to be able to cover all sleeping places and we will follow national guidelines to encourage their correct use as this is the current best practice at the beginning of the study. In the intervention arm, representing modern housing, we propose to modify existing thatched roof houses so that they will have

metal roofs, closed eaves, screened-air bricks, and screening on the doors and windows (n=400) and the control arm, representing traditional houses, will be left with thatched roofs and open eaves (n=400) until the end of the study.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

To assess whether improved housing reduces the burden of clinical malaria where coverage of LLINs is high. Incidence of clinical malaria determined by active case detection (ACD) and defined as body (axillary) temperature of $\geq 37.5^{\circ}\text{C}$, together with the presence of *Plasmodium falciparum* parasites detected by microscopy. Incidence will be measured from June to December in 2015 and 2016.

Secondary outcome measures

1. To determine whether improved housing reduces the rate of parasite infection, parasite density and anaemia in children. Prevalence of malaria infection, splenomegaly and anaemia determined by cross-sectional surveys at the beginning (June) and end of each rainy season (November /December) in 2015 and 2016. The presence of malaria parasites will be determined by microscopy, the presence of an enlarged spleen by palpation and anaemia quantified by measuring haemoglobin using a HemoCue.
2. To find out whether improved housing is associated with a rise in respiratory infections. Measure cough and either a respiratory rate of above the age specific cut-off or chest indrawing during twice weekly visits from June to December in 2015 and 2016.
3. To assess whether improved housing reduces vector density inside houses when compared with LLIN alone. Mean number of female *Anopheles gambiae* s.l./light trap/night. Estimated entomological inoculation rate (EIR) in each study arm (i.e. mean number of sporozoite infective bites/child/season) from June to December in 2015 and 2016. Collections will be made indoors using CDC light traps and the presence of vectors with sporozoites determined using an ELISA.
4. To determine whether improved housing is acceptable to the residents and sufficiently durable
5. To find out whether these interventions are cost effective
6. To develop a strategy for potential scale-up of improved housing

Overall study start date

01/11/2014

Completion date

01/02/2017

Eligibility

Key inclusion criteria

Houses must meet the following criteria to be selected:

1. Thatched roofs
2. Intact walls (no cracks)
3. Be single-storey square buildings
4. Open eaves

5. No more than four rooms
6. No ceiling (which is equivalent to closed eaves)
7. No screening
8. At least two resident children aged six months to 13 years old (needed in case the study child leaves the study)

Children must be:

1. Aged 6 months to 13 years old
2. Resident in houses enrolled in the study
3. Whose parents/carers give written, informed consent for their child to be included in the study

Assent will also be sought from eligible children >11 years old after the purpose of the study and what is required has been explained to them according to their capability. In the case of school-age children, only those who live in their village during term-time will be eligible for enrolment. In order for the results from this study to be as generalizable as possible, no distinctions will be made in terms of medical condition or physical health.

Participant type(s)

Healthy volunteer

Age group

Child

Lower age limit

6 Months

Upper age limit

13 Years

Sex

Both

Target number of participants

800 children; 400 in each arm

Total final enrolment

805

Key exclusion criteria

1. Children for whom informed consent is not or cannot be provided
2. Children aged under 6 months or over 13 years on 1st June for the year of survey
3. Children expected to be non-residence during several month of the transmission season

Date of first enrolment

01/01/2015

Date of final enrolment

01/06/2016

Locations

Countries of recruitment

England

Gambia

United Kingdom

Study participating centre

Durham University

School of Biological and Biomedical Sciences

Durham

United Kingdom

DH1 3LE

Sponsor information

Organisation

Durham University (UK)

Sponsor details

c/o Prof Patrick Hussey, Pro-Vice Chancellor for Science

Faculty of Science

Durham University

Science Laboratories

Durham

England

United Kingdom

DH1 3LE

+44 (0)191 334 2000

p.j.hussey@durham.ac.uk

Sponsor type

University/education

ROR

<https://ror.org/01v29qb04>

Funder(s)

Funder type

Research organisation

Funder Name

Global Health Trials (MRC-DfID-Wellcome Trust). MR/M007383/1 (UK)

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	03/06/2016		Yes	No
Results article		01/04/2021	13/04/2021	Yes	No